BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia
F Loscocco, G Visani, S Galimberti, A Curti… - Frontiers in …, 2019 - frontiersin.org
Not all chronic myeloid leukemia (CML) patients are cured with tyrosine kinase inhibitors
(TKIs), and a proportion of them develop resistance. Recently, continuous BCR-ABL gene …
(TKIs), and a proportion of them develop resistance. Recently, continuous BCR-ABL gene …
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis
H Wiendl, CC Gross - Nature Reviews Neurology, 2013 - nature.com
Multiple sclerosis (MS) is a debilitating neurological disorder involving autoimmune
destruction of myelin. Although the pathogenic mechanisms underlying MS are not fully …
destruction of myelin. Although the pathogenic mechanisms underlying MS are not fully …
Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2
Regulatory T (T reg) cells control progression to autoimmune diabetes in the BDC2. 5/NOD
mouse model by reining in natural killer (NK) cells that infiltrate the pancreatic islets …
mouse model by reining in natural killer (NK) cells that infiltrate the pancreatic islets …
[HTML][HTML] Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations
The persistence leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) despite
tyrosine kinase inhibition (TKI) may explain relapse after TKI withdrawal. Here we performed …
tyrosine kinase inhibition (TKI) may explain relapse after TKI withdrawal. Here we performed …
[HTML][HTML] Daclizumab: development, clinical trials, and practical aspects of use in multiple sclerosis
LE Baldassari, JW Rose - Neurotherapeutics, 2017 - Elsevier
Daclizumab is a humanized monoclonal antibody directed towards CD25, the alpha subunit
of the high-affinity interleukin (IL)-2 receptor. Daclizumab exerts its effects via multiple …
of the high-affinity interleukin (IL)-2 receptor. Daclizumab exerts its effects via multiple …
[图书][B] Quantitative pharmacology and individualized therapy strategies in development of therapeutic proteins for immune-mediated inflammatory diseases
H Zhou, DR Mould - 2019 - books.google.com
Thorough Overview Identifies and Addresses Critical Gaps in the Treatment of Several
Chronic Diseases With increasing numbers of patients suffering from Immune-Mediated …
Chronic Diseases With increasing numbers of patients suffering from Immune-Mediated …
Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Multiple Sclerosis–Peginterferon Beta‐1a, Daclizumab Beta, Natalizumab
X Hu, Y Hang, L Diao, KK Muralidharan… - … Therapy Strategies in …, 2019 - books.google.com
Multiple sclerosis (MS) is an autoimmune inflammatory disorder of central nervous system
(CNS), characterized by demyelination and variable degrees of axonal loss, resulting lesion …
(CNS), characterized by demyelination and variable degrees of axonal loss, resulting lesion …
[PDF][PDF] TRANSCRIPTIONAL AND EPIGENETIC REGULATORY PROGRAMS IN HEMATOPOIESIS AND LEUKEMOGENESIS
J Gucwa - 2016 - jscholarship.library.jhu.edu
The hematopoietic system provides a unique opportunity to study stem cell biology due to
the well-defined hierarchy of blood cell production. Hematopoietic stem cells (HSCs) …
the well-defined hierarchy of blood cell production. Hematopoietic stem cells (HSCs) …
[PDF][PDF] Pathogenic mediators in multiple sclerosis: GM-CSF and other TH cell-derived cytokines
F Jerg Hartmann - 2016 - zora.uzh.ch
Autoimmune diseases such as multiple sclerosis (MS) are a result of dysregulated immune
mechanisms, leading to the destruction of tissues by the immune system. In the case of MS …
mechanisms, leading to the destruction of tissues by the immune system. In the case of MS …